Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 2/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | DHCR24 | Q15392 | 6/20 | 0.43 |
| ▸ | VDR | P11473 | 9/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14208292 | 1.00 | CDC25A (0.46) | CDC25ACDC25BDHCR24VDRCYP19A1 | |
| SCHEMBL4155840 | 0.87 | CDC25A (0.43) | CDC25ACDC25BDHCR24VDRCYP19A1 | |
| SCHEMBL4155848 | 0.87 | CDC25A (0.43) | CDC25ACDC25BDHCR24VDRCYP19A1 | |
| SCHEMBL4155844 | 0.87 | CDC25A (0.43) | CDC25ACDC25BDHCR24VDRCYP19A1 | |
| SCHEMBL4160721 | 0.87 | CDC25A (0.43) | CDC25ACDC25BDHCR24VDRCYP19A1 | |
| SCHEMBL13090329 | 0.87 | CDC25A (0.43) | CDC25ACDC25BDHCR24VDRCYP19A1 | |
| SCHEMBL10125319 | 0.87 | CDC25A (0.43) | CDC25ACDC25BDHCR24VDRCYP19A1 | |
| SCHEMBL4160725 | 0.87 | CDC25A (0.43) | CDC25ACDC25BDHCR24VDRCYP19A1 | |
| SCHEMBL9925372 | 0.84 | CDC25A (0.44) | CDC25ACDC25BVDRCYP19A1 | |
| SCHEMBL18193607 | 0.84 | CDC25A (0.44) | CDC25ACDC25BVDRCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10479764-B2 | 2-methylene-(22E)-25-hexanoyl-24-oxo-26,27-cyclo-22-dehydro-19-nor-vitamin D analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2019-11-19 | — | — | US | disclosed |
| US-9834512-B2 | (22E)-2-methylene-26,27-cyclo-22-dehydro-1α-hydroxy-19-norvitamin D3 derivatives | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834512-B2 | (22E)-2-methylene-26,27-cyclo-22-dehydro-1α-hydroxy-19-norvitamin D3 derivatives | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2017-12-05 | — | — | US | disclosed |
| US-9073885-B2 | Vitamin D3 lactone derivatives | TEIJIN PHARMA LIMITED (JP) | 2015-07-07 | — | — | US | disclosed |
| US-8754067-B2 | 22-haloacetoxy-homopregnacalciferol analogs and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754067-B2 | 22-haloacetoxy-homopregnacalciferol analogs and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130005686-A1 | 2-Methylene-(22E)-25-Hexanoyl-24-OXO-26,27-Cyclo-22-Dehydro-19-Nor-Vitamin D Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005686-A1 | 2-Methylene-(22E)-25-Hexanoyl-24-OXO-26,27-Cyclo-22-Dehydro-19-Nor-Vitamin D Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-03 | — | — | US | disclosed |
| US-20120309719-A1 | (22E)-2-METHYLENE-26,27-CYCLO-22-DEHYDRO-1ALPHA-HYDROXY-19-NORVITAMIN D3 DERIVATIVES | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2012-12-06 | — | — | US | disclosed |
| WO-2012166938-A2 | (22E)-2-METHYLENE-26,27-CYCLO-22-DEHYDRO-1ALPHA-HYDROXY-19-NORVITAMIN D3 DERIVATIVES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-12-06 | — | — | WO | disclosed |
| US-20120149669-A1 | 22-Haloacetoxy-Homopregnacalciferol Analogs and Their Uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2012065050-A1 | 22-HALOACETOXY-HOMOPREGNACALCIFEROL ANALOGS AND THEIR USES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-05-18 | — | — | WO | disclosed |
| US-7915242-B2 | eczema, hypercalcemia, hyperparathyroidism, sarcoidosis, or vitamin D intoxication | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915242-B2 | eczema, hypercalcemia, hyperparathyroidism, sarcoidosis, or vitamin D intoxication | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479764-B2 | 2-methylene-(22E)-25-hexanoyl-24-oxo-26,27-cyclo-22-dehydro-19-nor-vitamin D analogs | VDR, CYP24A1, CYP27B1 | CDC25A 2459/4885CDC25B 2313/4885DHCR24 19/4885 |
| US-20120149669-A1 | 22-Haloacetoxy-Homopregnacalciferol Analogs and Their Uses | CYP27B1, CYP27A1, MCL1 | CDC25A 3126/4885CDC25B 2923/4885DHCR24 9/4885 |
| US-20130005686-A1 | 2-Methylene-(22E)-25-Hexanoyl-24-OXO-26,27-Cyclo-22-Dehydro-19-Nor-Vitamin D Analogs | VDR, CYP24A1, CYP27B1 | CDC25A 2459/4885CDC25B 2313/4885DHCR24 19/4885 |
| US-20120309719-A1 | (22E)-2-METHYLENE-26,27-CYCLO-22-DEHYDRO-1ALPHA-HYDROXY-19-NORVITAMIN D3 DERIVATIVES | CYP24A1, CYP2R1, CYP27B1 | CDC25A 1851/4885CDC25B 1280/4885DHCR24 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.